ライフサイエンスコーパス: epithelial ovarian carcinoma

1 tients with platinum-resistant or refractory epithelial ovarian carcinoma.

2 l cells is present in the normal ovaries and epithelial ovarian carcinoma.

3 ells derived from nine normal ovaries and 21 epithelial ovarian carcinoma.

4 ological entity compared with grade 1 serous epithelial ovarian carcinoma.

5 vanced and relapsed peritoneal metastasis in epithelial ovarian carcinoma.

6 criterion being a pathological diagnosis of epithelial ovarian carcinoma.

7 primary breast carcinomas and in 55 primary epithelial ovarian carcinomas.

8 ve serum TF levels in 98 women with invasive epithelial ovarian carcinoma, 30 with low malignant pote

9 this study, we show that in human and mouse epithelial ovarian carcinoma and mouse lung carcinoma, t

10 allelic loss on chromosome 7q31 in invasive epithelial ovarian carcinomas and borderline ovarian tum

11 Epithelial ovarian carcinomas are particularly deadly du

12 Three main groups of samples (epithelial ovarian carcinoma, borderline ovarian tumours

13 Cytotoxicity assays on human epithelial ovarian carcinoma cisplatin-sensitive and -re

14 function in benign tissue and in high-grade epithelial ovarian carcinoma (EOC) in parallel with expl

15 acizumab in patients with platinum-resistant epithelial ovarian carcinoma (EOC) or peritoneal serous

16 rm survival rates for patients with advanced epithelial ovarian carcinoma (EOC) remain disappointing,

17 teinases in i.p. metastatic dissemination of epithelial ovarian carcinoma (EOC).

18 ly identified in gene expression profiles of epithelial ovarian carcinomas (EOC) is the gene for huma

19 clinical outcome of high-grade serous (HGS) epithelial ovarian carcinomas (EOC), we evaluated the as

20 e glycosyltransferase GnT-III is elevated in epithelial ovarian carcinomas (EOCs) and leads to the pr

21 f targeted therapy to date in the setting of epithelial ovarian carcinoma has come from angiogenesis

22 es (P-A and P-C) in the destruction of human epithelial ovarian carcinoma heterotransplanted in the n

23 evelopment and progression of human invasive epithelial ovarian carcinomas (IEOC).

24 hromosomes 5 and 6 in 29 primary early-stage epithelial ovarian carcinomas including 3 microscopicall

25 Epithelial ovarian carcinoma is the most common cause of

26 en with platinum-naive or platinum-sensitive epithelial ovarian carcinoma may be indicated.

27 Previous allelotyping studies of epithelial ovarian carcinoma suggest that loss of hetero

28 ere more mesenchymal when compared with pure epithelial ovarian carcinomas, supporting the conversion

29 Epithelial ovarian carcinoma tissues express high levels

30 profiled microRNA (miR) expression in serous epithelial ovarian carcinomas to assess the possibility

31 sessment of clinical outcomes with regard to epithelial ovarian carcinoma tumor methylation to date.

32 The most common ovarian cancer is epithelial ovarian carcinoma, which is characterised by

33 ion (32P) therapy in patients with stage III epithelial ovarian carcinoma who have no detectable evid

34 n has modest activity in women with advanced epithelial ovarian carcinoma who have progressed or not

35 a multicenter, phase II study of women with epithelial ovarian carcinoma who relapsed after one or t

36 analysis was performed on 300 patients with epithelial ovarian carcinoma with at least one measureme